In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 291 to 300 of 373

TitleTypeExpected publication date
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]Technology appraisal guidanceTBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Technology appraisal guidanceTBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [ID6297]Technology appraisal guidanceTBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]Technology appraisal guidance
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Technology appraisal guidanceTBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]Technology appraisal guidance
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]Technology appraisal guidanceTBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Technology appraisal guidance
Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All